Tech News St. Vincent & Grenadines
SEE OTHER BRANDS

Get your science and technology news from Saint Vincent and the Grenadines

Tech News St. Vincent & Grenadines: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech News St. Vincent & Grenadines.

Press releases published on August 6, 2025

Quick Custom Intelligence Partners with ComOps to Offer Secure, Scalable Off-Site Human Player-Development Services for Casinos

Quick Custom Intelligence Partners with ComOps to Offer Secure, Scalable Off-Site Human Player-Development Services for Casinos

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI), the global leader in AI-driven casino analytics, today announced a strategic partnership with ComOps, a hospitality performance partner delivering support-as-a-service solutions …

Computer Modelling Group Announces First Quarter Results and Quarterly Dividend

Computer Modelling Group Announces First Quarter Results and Quarterly Dividend

CALGARY, Alberta, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Computer Modelling Group Ltd. (“CMG Group” or the “Company”) announces its financial results for the three months ended June 30, 2025, and the approval by its Board of Directors (the “Board”) of the …

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from …

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 …

SilentSwap and Own. App Partner to Bring Privacy-Powered Asset Swaps to Social Media

SilentSwap and Own. App Partner to Bring Privacy-Powered Asset Swaps to Social Media

New York City, Aug. 06, 2025 (GLOBE NEWSWIRE) -- New integration lends SilentSwap privacy to enable Own. App users secure and seamless wallet-to-wallet asset swaps across major blockchain networks New York City Aug 6, 2025 (Premium) SilentSwap, a non- …

Intuitive Machines Expands Deep Space Navigation Services with Agreement to Acquire KinetX, Positioning Itself for Constellation Management and Moon-to-Mars Data Relay

Intuitive Machines Expands Deep Space Navigation Services with Agreement to Acquire KinetX, Positioning Itself for Constellation Management and Moon-to-Mars Data Relay

HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR) (“Intuitive Machines” or the “Company”), a leading space technology, infrastructure, and services company, today announced it has signed a definitive agreement to acquire …

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations …

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery …

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and …

Orezone Provides Notice of Q2-2025 Results

Orezone Provides Notice of Q2-2025 Results

VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone”) will announce its second quarter 2025 results on Wednesday, August 13, 2025, after market close. The announcement will be followed …

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated …

MKS Inc. Reports Second Quarter 2025 Financial Results

MKS Inc. Reports Second Quarter 2025 Financial Results

Revenue of $973 million, above the high end of guidance GAAP net income of $62 million and net income per diluted share of $0.92, each above the midpoint of guidance Adjusted EBITDA of $240 million, above the high end of guidance, and Non-GAAP net earnings …

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through Week 12 on track for Q4 2025 Ongoing …

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. …

Certara Reports Second Quarter 2025 Financial Results 

Certara Reports Second Quarter 2025 Financial Results 

RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 …

GoHealth to Announce Strategic Capital and Governance Actions to Support Long-Term Value Creation and Second Quarter 2025 Results

GoHealth to Announce Strategic Capital and Governance Actions to Support Long-Term Value Creation and Second Quarter 2025 Results

CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, will announce strategic capital and governance actions to support long-term value …

Silvaco Reports Second Quarter 2025 Financial Results

Silvaco Reports Second Quarter 2025 Financial Results

Achieved Gross Bookings of $12.91 Million and Revenue of $12.05 Million Landed 10 New Logos in Photonics, Automotive, Military, Foundry, and Power Achieved Trailing Twelve-Month ACV Growth of 26% SANTA CLARA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- …

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year …

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) …

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions